Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 May 19:10:9.
doi: 10.1186/1471-2490-10-9.

A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

Affiliations
Meta-Analysis

A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

Ary Serpa Neto et al. BMC Urol. .

Abstract

Background: Osteoporosis could be associated with the hormone therapy for metastatic prostate carcinoma (PCa) and with PCa per se. The objective of this review is to determine the incidence of bone loss and osteoporosis in patients with PCa who are or are not treated with hormone therapy (ADT).

Methods: The Medline, Embase, Cancerlit, and American Society of Clinical Oncology Abstract databases were searched for published studies on prostate cancer and bone metabolism. The outcomes assessed were: fracture, osteoporosis and osteopenia.

Results: Thirty-two articles (116,911 participants) were included in the meta-analysis. PCa patients under ADT had a higher risk of osteoporosis (RR, 1.30; p < 0.00001) and a higher risk of fractures (RR, 1.17; p < 0.00001) as compared to patients not under ADT. The total bone mineral density was lower in patients under ADT when compared with patients not under ADT (p = 0.031) but it was similar to bone mineral density found in healthy controls (p = 0.895). The time of androgen deprivation therapy correlated negatively with lumbar spine and total hip bone mineral density (Spearman's rho = -0.490 and -0.773; p = 0.028 and 0.001, respectively) and with total hip t score (Spearman's rho = -0.900; p = 0.037).

Conclusion: We found consistent evidence that the use of androgen deprivation therapy in patients with PCa reduces bone mineral density, increasing the risk of fractures in these patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the meta-analysis.
Figure 2
Figure 2
Scatter plot of lumbar spine (black circles) and total hip (white circles) BMD and ADT time.
Figure 3
Figure 3
Adjusted risk ratios. A, Adjusted risk ratio of osteoporosis for patients under ADT as compared to patients not under ADT. B, Adjusted risk ratio of osteoporosis for patients with PCa as compared to healthy controls.
Figure 4
Figure 4
Adjusted risk ratio of fractures for patients under ADT as compared to patients not under ADT.
Figure 5
Figure 5
Funnel plots. A, Begg funnel plot with pseudo 95% CIs for osteoporosis analysis of patients under ADT (Figure 2A). B, Begg funnel plot with pseudo 95% CIs for fracture analysis of patients under ADT (Figure 3).

Similar articles

Cited by

References

    1. Frydenberg M, Stricker PD, Kaye KW. Prostate cancer diagnosis and treatment. Lancet. 1997;349:1681–7. doi: 10.1016/S0140-6736(96)07393-X. - DOI - PubMed
    1. Bubendorf L, Schopfer A, Wagner U. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol. 2000;31:578–83. doi: 10.1053/hp.2000.6698. - DOI - PubMed
    1. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88:2989–94. doi: 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q. - DOI - PubMed
    1. Eaton CL, Colby L, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates treatment. Cancer Treat Rev. 2003;29:189–98. doi: 10.1016/S0305-7372(03)00071-9. - DOI - PubMed
    1. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol. 2004;45:26–34. doi: 10.1016/j.eururo.2003.10.003. - DOI - PubMed

Substances